Vaccines
•47 stocks
•
Total Market Cap: Loading...
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (47)
| Company | Market Cap | Price |
|---|---|---|
|
MRK
Merck & Co., Inc.
The company markets vaccines (Capvaxive) and has historical Gardasil sales, making vaccines a core product category.
|
$295.53B |
$119.10
+3.15%
|
|
PFE
Pfizer Inc.
Pfizer's vaccines portfolio (e.g., Comirnaty and other RSV vaccines) is a core, revenue-driving product line.
|
$156.70B |
$27.56
+1.25%
|
|
CVS
CVS Health Corporation
CVS administers vaccines across its pharmacy network, a direct service offering.
|
$98.13B |
$77.25
+0.61%
|
|
TAK
Takeda Pharmaceutical Company Limited
Takeda markets vaccines (QDENGA) and maintains a vaccines-focused portfolio.
|
$55.67B |
$17.82
+0.25%
|
|
ZTS
Zoetis Inc.
Zoetis markets vaccines for companion animals and livestock, a major revenue and product category.
|
$53.93B |
$122.38
+2.81%
|
|
BNTX
BioNTech SE
BioNTech develops and sells vaccines, including its mRNA vaccine platform, a core direct product category.
|
$24.75B |
$102.82
+0.69%
|
|
MRNA
Moderna, Inc.
Direct vaccines products (Spikevax and pipeline vaccines) are Moderna's core revenue drivers and product line.
|
$20.99B |
$53.73
-1.73%
|
|
ELAN
Elanco Animal Health Incorporated
Vaccines are a major product category and a focus of Elanco's innovation pipeline.
|
$11.77B |
$23.69
+2.42%
|
|
RDY
Dr. Reddy's Laboratories Limited
Strategic emphasis on vaccines, including RSV vaccine programs.
|
$11.10B |
$13.29
+1.80%
|
|
PCVX
Vaxcyte, Inc.
PCVX directly develops and is advancing vaccine products (VAX-24, VAX-31) including pneumococcal conjugate vaccines, making Vaccines the core investable product category.
|
$8.16B |
$62.34
+0.23%
|
|
IBRX
ImmunityBio, Inc.
Vaccine vectors and vaccines pipeline (hAd5 vectors targeting TAAs).
|
$7.58B |
$7.68
+6.00%
|
|
PAHC
Phibro Animal Health Corporation
Vaccines are explicitly listed as a pillar of the Animal Health segment.
|
$2.31B |
$57.04
+5.86%
|
|
DVAX
Dynavax Technologies Corporation
HEPLISAV-B is a hepatitis B vaccine, representing the company's flagship vaccine product.
|
$1.82B |
$15.49
-0.03%
|
|
CAPR
Capricor Therapeutics, Inc.
Capricor is developing a vaccine candidate via its StealthX platform in collaboration with Project NextGen.
|
$1.59B |
$34.70
+0.32%
|
|
NVAX
Novavax, Inc.
Novavax develops, manufactures, and commercializes vaccines (e.g., Nuvaxovid), placing it squarely in the vaccines product category.
|
$1.44B |
$8.82
+2.14%
|
|
AHG
Akso Health Group
Vaccine research centers planned (AIDS and Covid-19) within the strategy.
|
$1.30B |
$2.33
-0.85%
|
|
CVAC
CureVac N.V.
The company is actively developing infectious disease vaccines using its mRNA backbone (Vaccines).
|
$1.05B |
$4.66
|
|
OPK
OPKO Health, Inc.
OPKO is advancing vaccines via EBV vaccine collaboration, a core vaccine development activity.
|
$951.95M |
$1.23
+1.65%
|
|
SLS
SELLAS Life Sciences Group, Inc.
GPS is a WT1-targeted cancer vaccine, fitting the Vaccines category as a therapeutic vaccine approach.
|
$743.55M |
$5.24
+6.19%
|
|
OCGN
Ocugen, Inc.
OCU500 represents an inhaled mucosal vaccine platform with a COVID-19 vaccine IND.
|
$621.52M |
$2.00
+3.37%
|
|
VALN
Valneva SE
Valneva directly manufactures and sells vaccines (e.g., VLA15 Lyme vaccine, IXCHIQ chikungunya vaccine, IXIARO, DUKORAL) and is advancing multiple vaccine candidates, making vaccines its core product category.
|
$483.94M |
$5.96
-0.25%
|
|
EBS
Emergent BioSolutions Inc.
EBS directly develops and manufactures vaccines and vaccine-derived MCMs (BioThrax, ACAM2000, TEMBEXA) for government/public health programs.
|
$462.70M |
$8.81
+2.20%
|
|
ARCT
Arcturus Therapeutics Holdings Inc.
Direct product: vaccines pipeline and KOSTAIVE vaccine production and commercialization.
|
$251.45M |
$8.87
+0.34%
|
|
VXRT
Vaxart, Inc.
VXRT directly develops and advances vaccines (norovirus, COVID-19, avian influenza) using its VAAST oral vaccine platform.
|
$170.96M |
$0.75
|
|
TNXP
Tonix Pharmaceuticals Holding Corp.
TNX-801 is a live virus vaccine candidate for mpox/smallpox, placing Tonix in vaccines development with potential commercialization.
|
$164.64M |
$13.96
-1.17%
|
|
ORMP
Oramed Pharmaceuticals Inc.
Oravax Medical Inc., in which Oramed holds a majority stake, focuses on oral vaccines, making Vaccines a direct product category for the company.
|
$154.43M |
$3.88
+0.52%
|
|
ELTX
Elicio Therapeutics, Inc.
Lead product candidate is a cancer vaccine/immunotherapy, aligning with Vaccines.
|
$144.76M |
$8.74
-1.35%
|
|
HLVX
HilleVax, Inc.
Direct vaccine development activity with norovirus vaccine candidates (HIL-216.00) and existing vaccine focus.
|
$104.79M |
$2.09
|
|
ANIX
Anixa Biosciences, Inc.
Breast and ovarian cancer vaccines constitute a direct vaccine product line.
|
$97.13M |
$2.92
+3.00%
|
|
FBIO
Fortress Biotech, Inc.
Fortress’ portfolio includes vaccine programs (Helocyte's Triplex CMV vaccine), aligning with Vaccines.
|
$73.25M |
$2.35
+0.21%
|
|
INO
Inovio Pharmaceuticals, Inc.
Pipeline includes Ebola vaccine booster (INO-4201) and other vaccine approaches; company develops vaccines using DNA plasmids.
|
$63.75M |
$1.20
+3.02%
|
|
IPA
ImmunoPrecise Antibodies Ltd.
Vaccines program (universal dengue vaccine) as an internal asset and potential product.
|
$56.31M |
N/A
|
|
DYAI
Dyadic International, Inc.
Company has vaccine-related programs and antigen work (e.g., mpox ferritin nanoparticle vaccine antigen) via its platforms, aligning with vaccines.
|
$31.66M |
$0.87
-1.35%
|
|
PDSB
PDS Biotechnology Corporation
PDS0101/Versamune HPV functions as a therapeutic cancer vaccine, aligning with the Vaccines category.
|
$29.85M |
$0.66
+2.39%
|
|
TVGN
Tevogen Bio Holdings Inc.
TVGN 489 and the TVGN vaccine program indicate vaccine development capabilities (T cell vaccine approach).
|
$29.33M |
$7.42
+16.59%
|
|
EVAX
Evaxion Biotech A/S
Evaxion develops vaccines, including EVX-01 for cancer and multiple infectious-disease vaccine programs.
|
$28.11M |
$4.50
+8.70%
|
|
PMN
ProMIS Neurosciences, Inc.
PMN311 and PMN400 indicate a vaccine development program targeting amyloid and alpha-synuclein epitopes.
|
$24.82M |
$11.46
-3.25%
|
|
BRNS
Barinthus Biotherapeutics plc
Pipeline includes vaccines (VTP-500 MERS) and vaccine-focused platforms.
|
$24.09M |
$0.62
+4.91%
|
|
NWBO
Northwest Biotherapeutics, Inc.
DCVax-L and DCVax-Direct are therapeutic vaccines for cancer, aligning with Vaccines.
|
$22.35M |
$0.20
|
|
SNGX
Soligenix, Inc.
ThermoVax vaccine thermostabilization platform and RiVax vaccine program place Soligenix in Vaccines.
|
$12.61M |
$1.25
+6.41%
|
|
IMNN
Imunon, Inc.
PlaCCine platform includes DNA-based vaccines (e.g., COVID-19 candidate), aligning with Vaccines.
|
$9.10M |
$4.16
+0.73%
|
|
MDCX
Medicus Pharma Ltd. Common Stock
Strategic collaboration on thermostable vaccines indicates vaccine development activity.
|
$8.68M |
$0.35
+15.22%
|
|
BCTX
BriaCell Therapeutics Corp.
Bria-IMT Bria-OTS involve cellular vaccine approaches in cancer, aligning with Vaccines.
|
$8.35M |
$4.40
+1.85%
|
|
IMRN
Immuron Limited
Travelan IMM-124E prophylactic product aligns with vaccines/immune prophylaxis category.
|
$5.60M |
$0.95
+12.38%
|
|
ALZN
Alzamend Neuro, Inc.
ALZN002 is described as a vaccine-based active immunotherapy approach for Alzheimer's.
|
$4.26M |
$1.11
+11.00%
|
|
GOVX
GeoVax Labs, Inc.
GeoVax directly develops and manufactures vaccines using its MVA platform for infectious diseases (Mpox/smallpox and COVID-19 programs).
|
$3.20M |
$3.16
+9.72%
|
|
IOBT
IO Biotech, Inc.
IO Biotech's lead candidate is a therapeutic cancer vaccine (off-the-shelf cancer vaccines) and IO102-IO103 is built on a vaccine platform.
|
$3.16M |
$0.05
+2.08%
|
Loading company comparison...
Loading industry trends...
Loading research report...
